Addition of Nimotuzumab to Standard TPF Regimen in Locally Advanced Head and Neck Cancer: A Single Institutional Study

Table 2

Overall analysis of study population (data are expressed in median, range, and number or percentage; PFS, progression-free survival; OS, overall survival).

Variables	N	Median PFS	Median OS	value
Overall	20	16 months (7.2–20.6 months)	38 months (32–44 months)
Anatomic site
Oral cavity	12 (60%)		34.5 months
Hypopharynx	6 (30%)		38 months
Oropharynx	2 (10%)		35 months
Overall response rate after induction	75%
Complete response	2 (10%)
Partial response	13 (65%)
Stable disease	2 (10%)
Progressive disease	3 (15%)
Overall response rate after CRT	65%
Complete response	6 (30%)	Not reached	Not reached
Partial response	7 (35%)	17.6 months	34.5 months
Stable disease	2 (10%)	8.1 months	31 months
Progressive disease	5 (25%)	6.7 months	17 months